NDA 022117 · Abbvie
Saphris
Asenapine Maleate · Sublingual
NovelLast checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 13, 2009
Approved uses
7
Original approval plus efficacy supplements
Registered trials
51
35 Phase 3, 0 recruiting
FAERS reports
7,825
3,466 serious, 279 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SAPHRIS ® (asenapine) is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1, 5.2 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SAPHRIS is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 , 5.2 )
What it is approved for
From the label in effect Jan 31, 2025.
1 INDICATIONS AN D USAGE SAPHRIS is indicated for: Schizophrenia in adults [see Clinical Studies ( 14.1 )] Bipolar I disorder [see Clinical Studies ( 14.2 )] • Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age • Adjunctive treatment to lithium or valproate in adults • Maintenance monotherapy treatment in adults SAPHRIS is an atypical antipsychotic indicated for ( 1 ): Schizophrenia in adults Bipolar I disorder ○ Acute monotherapy treatment of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age ○ Adjunctive treatment to lithium or valproate in adults ○ Maintenance monotherapy treatment in adults
Mechanism: The mechanism of action of asenapine, in schizophrenia and bipolar I disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 13, 2017 Supplement 20 · Efficacy LabelLetter
- Jan 13, 2017 Supplement 21 · Efficacy LabelLetter
- Mar 12, 2015 Supplement 18 · Efficacy · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
- Mar 12, 2015 Supplement 19 · Efficacy · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
- Sep 3, 2010 Supplement 3 · Efficacy LetterLabel
- Sep 3, 2010 Supplement 4 · Efficacy LabelLetter
- Aug 13, 2009 Original approval · Type 1 - New Molecular Entity NovelOther Important Information from FDALetterLabel
3 products under this application
- SAPHRIS · ASENAPINE MALEATE EQ 5MG BASE · TABLET, SUBLINGUAL · Prescription · TE AB
- SAPHRIS · ASENAPINE MALEATE EQ 10MG BASE · TABLET, SUBLINGUAL · Prescription · TE AB
- SAPHRIS · ASENAPINE MALEATE EQ 2.5MG BASE · TABLET, SUBLINGUAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Asenapine" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00212784 · 1,225 participants · Start Sep 4, 2003 · Primary completion Mar 15, 2006
Drug: asenapine; olanzapine · For: Schizophrenia; Schizoaffective Disorder
- To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00150176 · 831 participants · Start Apr 2005 · Primary completion Jun 2008
Drug: Asenapine - Open Label; Placebo - Double Blind and 1 more · For: Schizophrenia
- Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.Pivotal-lookingCompleted
Noven Pharmaceuticals, Inc.Industry
NCT02876900 · 617 participants · Start Aug 2016 · Primary completion Jun 2018
Drug: Low Dose Asenapine maleate transdermal patch; High Dose Asenapine maleate transdermal patch and 1 more · For: Schizophrenia
Sites: Jersey City, New Jersey
- Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01396291 · 561 participants · Start Dec 2011 · Primary completion Apr 2015
Drug: asenapine; placebo · For: Bipolar 1 Disorder
Sites: Anaheim, California; Chino, California; Escondido, California · 80 sites in all
- 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01098110 · 532 participants · Start May 25, 2010 · Primary completion Apr 14, 2014
Drug: Asenapine 5 mg; Asenapine 10 mg and 1 more · For: Schizophrenia
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00143182 · 504 participants · Start Jan 7, 2005 · Primary completion Jun 28, 2006
Drug: Asenapine; Olanzapine · For: Bipolar Disorder
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00159796 · 489 participants · Start Dec 14, 2004 · Primary completion Mar 28, 2006
Drug: Asenapine; Olanzapine and 1 more · For: Bipolar Disorder
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00159744 · 488 participants · Start Nov 30, 2004 · Primary completion Apr 29, 2006
Drug: Asenapine; Olanzapine and 1 more · For: Bipolar Disorder
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective806
- sedation667
- suicide attempt651
- inappropriate schedule of drug administration557
- weight increased537
- dyskinesia520
- dystonia496
- blood glucose increased477
- sexual dysfunction427
- anosognosia423
- blood prolactin abnormal413
- metabolic disorder413
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 17 |
| 2010 | 1,716 |
| 2011 | 1,017 |
| 2012 | 1,003 |
| 2013 | 1,397 |
| 2014 | 197 |
| 2015 | 152 |
| 2016 | 279 |
| 2017 | 215 |
| 2018 | 206 |
| 2019 | 306 |
| 2020 | 241 |
| 2021 | 265 |
| 2022 | 288 |
| 2023 | 232 |
| 2024 | 111 |
| 2025 | 109 |
| 2026 | 74 |
Recalls
1 FDA enforcement reports for this application.
May 18, 2017 · Class II · Terminated
Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Saphris (Asenapine Maleate)
2024 spending
$7.2M
Beneficiaries
933
6,204 claims
Per beneficiary
$7,683
$19.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $107,720,607 |
| 2021 | $39,919,860 |
| 2022 | $12,288,835 |
| 2023 | $9,012,113 |
| 2024 | $7,167,784 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.
Lin X, Siafis S, Tian J, et al. · CNS Drugs 2025 · Systematic Review, Meta-Analysis
- Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis.
Barton BB, Segger F, Fischer K, et al. · Expert Opin Drug Saf 2020 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.